[{"quiz_id": "ABMS20260101_gemini-3-pro-preview_p04", "question_id": "ABMS20260101_gemini-3-pro-preview_p04-001", "question": "A 78-year-old female is evaluated for progressive visual dysfunction. She reports difficulty reading and navigating her home, often bumping into doorframes. Her family notes she cannot reach for objects accurately (optic ataxia) and cannot describe the entire scene of a picture (simultanagnosia). Memory and language are relatively preserved. MRI shows predominant atrophy of the parietal and occipital lobes. What is the most likely underlying pathology?", "options": ["Lewy Body Disease", "Prion Disease (CJD)", "Alzheimer's Disease pathology (Amyloid plaques/Tau tangles)", "Frontotemporal Lobar Degeneration (TDP-43)", "Vascular Dementia"], "answer": "C", "answer_index": 2, "explanation": "This patient presents with Posterior Cortical Atrophy (PCA), also known as Benson's syndrome. The clinical hallmark is Balint's syndrome (simultanagnosia, optic ataxia, oculomotor apraxia) and Gerstmann's syndrome. Despite the atypical visual presentation, the underlying pathology in the vast majority (>80%) of PCA cases is Alzheimer's disease (amyloid plaques and neurofibrillary tangles).", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "abms_specialty": "Geriatrics", "abms_source": "target_topic", "source_label_raw": "Geriatrics", "source_quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "source_question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-007", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gemini-3-pro-preview/20251223T232137723Z_gemini-3-pro-preview_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251223T232137723Z_gemini-3-pro-preview_seed130.jsonl", "pred": "C", "model_outputs": "Based on the clinical presentation, the patient is exhibiting signs of Posterior Cortical Atrophy (PCA), also known as Benson's syndrome. Key features include:\n\n1.  Visuospatial and visuoperceptual deficits: Difficulty reading, navigating, and bumping into objects.\n2.  Balint's Syndrome components: The patient presents with optic ataxia (inability to reach for objects under visual guidance) and simultanagnosia (inability to perceive the visual field as a whole), which are classic signs of parietal-occipital dysfunction.\n3.  Preserved Memory: Unlike typical Alzheimer's presentations, memory and language are spared in the early stages of PCA.\n4.  Neuroimaging: Atrophy restricted to or predominant in the parietal and occipital lobes.\n\nWhile PCA is a clinical syndrome, the underlying neuropathology in the vast majority of cases (estimates range from 80% to over 90%) is Alzheimer's Disease (beta-amyloid plaques and neurofibrillary tangles), but with a distribution of pathology affecting the visual association cortex rather than the hippocampus and entorhinal cortex initially. While Lewy Body Disease and Corticobasal Degeneration can rarely cause this syndrome, Alzheimer's pathology is by far the most likely etiology.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_gemini-3-pro-preview_p04", "question_id": "ABMS20260101_gemini-3-pro-preview_p04-002", "question": "A 3-day-old neonate presents with intractable seizures refractory to phenobarbital, phenytoin, and levetiracetam. The EEG shows a burst-suppression pattern. Administration of intravenous pyridoxine yields no improvement. Subsequent administration of pyridoxal-5'-phosphate results in immediate cessation of clinical and electrographic seizure activity. Which enzyme is deficient?", "options": ["Antiquitin (ALDH7A1)", "Pyridox(am)ine 5'-phosphate oxidase (PNPO)", "Glutamic acid decarboxylase (GAD)", "GABA transaminase", "Succinic semialdehyde dehydrogenase"], "answer": "B", "answer_index": 1, "explanation": "Pyridoxine-dependent epilepsy (ALDH7A1 deficiency) responds to pyridoxine. However, patients with PNPO deficiency cannot convert pyridoxine to the active form, pyridoxal-5'-phosphate (PLP). They present with similar intractable seizures but require PLP specifically for treatment.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "target_topic", "source_label_raw": "Pediatrics", "source_quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "source_question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-002", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gemini-3-pro-preview/20251223T232137723Z_gemini-3-pro-preview_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251223T232137723Z_gemini-3-pro-preview_seed128.jsonl", "pred": "B", "model_outputs": "The clinical scenario describes a neonate with seizures refractory to conventional antiepileptic drugs and, crucially, refractory to pyridoxine (vitamin B6) but responsive to pyridoxal-5'-phosphate (PLP).\n\n1.  Antiquitin (ALDH7A1) deficiency causes Pyridoxine-Dependent Epilepsy (PDE). In PDE, a defect in the antiquitin enzyme leads to the accumulation of $\\alpha$-aminoadipic semialdehyde ($\\alpha$-AASA) and $\\Delta^1$-piperideine-6-carboxylate (P6C). P6C condenses with PLP, inactivating it. While these patients have a functional need for PLP, the standard clinical feature is a dramatic response to pyridoxine supplementation, which overwhelms the sequestration effect. Since this patient did *not* respond to pyridoxine, this diagnosis is less likely.\n2.  Pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency impairs the conversion of pyridoxine 5'-phosphate (PNP) and pyridoxamine 5'-phosphate (PMP) into the active coenzyme pyridoxal-5'-phosphate (PLP). Because the enzyme responsible for creating the active form from precursors (like pyridoxine) is defective, supplementation with pyridoxine is ineffective. However, direct administration of PLP bypasses the metabolic block, leading to cessation of seizures. This matches the description perfectly.\n3.  Options C, D, and E relate to GABA metabolism directly but do not exhibit this specific pattern of cofactor responsiveness (pyridoxine resistance with PLP responsiveness).\n\nThe answer is (B)\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_gemini-3-pro-preview_p04", "question_id": "ABMS20260101_gemini-3-pro-preview_p04-003", "question": "A 45-year-old victim of a residential fire is intubated for airway protection. Due to suspected cyanide toxicity, a specific antidote is administered. Two hours later, the patient requires continuous renal replacement therapy (CRRT) for severe acidosis and acute kidney injury. Shortly after initiation, the CRRT machine repeatedly alarms and stops due to a 'Blood Leak' error, despite visual inspection of the effluent showing no frank blood. What is the mechanism of this technical complication?", "options": ["Hemolysis induced by the antidote", "Rhabdomyolysis myoglobin filtering", "Optical interference by the antidote", "Precipitation of antidote in the filter", "Coagulation of the filter membrane"], "answer": "C", "answer_index": 2, "explanation": "The patient received hydroxocobalamin (cyanokit), which has an intense red color. This chromophore passes into the ultrafiltrate/dialysate and is detected by the optical blood leak detector of the dialysis machine, causing a false-positive alarm that halts therapy. It also interferes with co-oximetry (falsely elevating HbCO) and colorimetric chemistry labs (creatinine, lactate) for days.", "generator_model": "gemini-3-pro-preview", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Emergency Medicine", "abms_specialty": "Emergency Medicine", "abms_source": "topics_mapped", "source_label_raw": "Emergency Medicine", "source_quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed125", "source_question_id": "20251129T125426901Z_gemini-3-pro-preview_seed125-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gemini-3-pro-preview/20251129T125426901Z_gemini-3-pro-preview_seed125", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251129T125426901Z_gemini-3-pro-preview_seed125.jsonl", "pred": "C", "model_outputs": "The clinical scenario describes a patient treated with hydroxocobalamin (Cyanokit) for suspected cyanide poisoning following smoke inhalation from a residential fire. Hydroxocobalamin is the preferred antidote in this setting because it does not compromise oxygen-carrying capacity (unlike nitrite-based kits which induce methemoglobinemia).\n\nHydroxocobalamin is a cobalt-containing molecule with a deep red color. Upon administration, it causes a distinctive reddish discoloration of the patient's plasma, mucous membranes, and urine. Because hydroxocobalamin is water-soluble and relatively small (approx 1.3 kDa), it is cleared across the hemofilter during renal replacement therapy (CRRT).\n\nCRRT machines utilize an optical blood leak detector on the effluent (dialysate/ultrafiltrate) line to identify membrane ruptures. This sensor typically operates by measuring light transmission or absorbance to detect red blood cells (hemoglobin). When hydroxocobalamin filters into the effluent, it turns the fluid red. The optical sensor detects this change in color/absorbance and falsely interprets it as the presence of blood, triggering a \"Blood Leak\" alarm and stopping the blood pump, even though the filter membrane is intact.\n\n*   Option A: Hydroxocobalamin does not typically cause hemolysis.\n*   Option B: While rhabdomyolysis is possible in fire victims, the specific mention of the antidote and the timing strongly points toward the known interference of hydroxocobalamin.\n*   Option D & E: These would likely trigger pressure alarms (e.g., transmembrane pressure) rather than blood leak alarms.\n\nTherefore, the mechanism is the red pigmentation of the drug causing optical interference with the safety sensor.\n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_gemini-3-pro-preview_p04", "question_id": "ABMS20260101_gemini-3-pro-preview_p04-004", "question": "A 35-year-old female undergoes a cone biopsy for CIN 3. Pathology reveals invasive squamous cell carcinoma with 2 mm depth of invasion and 5 mm horizontal spread. Lymphovascular space invasion (LVSI) is extensively present. Margins are negative. Imaging shows no lymphadenopathy. She desires future fertility. According to NCCN guidelines, what is the recommended management?", "options": ["Simple trachelectomy", "Radical trachelectomy with pelvic lymph node assessment", "Conization with negative margins is sufficient", "Simple hysterectomy", "Pelvic radiation therapy"], "answer": "B", "answer_index": 1, "explanation": "The patient has Stage IA1 cervical cancer (invasion <= 3mm). However, the presence of Lymphovascular Space Invasion (LVSI) significantly increases the risk of lymph node metastasis and recurrence. Therefore, simple excision (cone) or simple trachelectomy/hysterectomy is insufficient. The recommended management for fertility preservation in IA1 with LVSI is radical trachelectomy with pelvic lymph node assessment (sentinel node or dissection).", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Obstetrics and Gynecology", "abms_specialty": "Obstetrics and Gynecology", "abms_source": "topics_mapped", "source_label_raw": "gynecology", "source_quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "source_question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-010", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gemini-3-pro-preview/20251129T125426901Z_gemini-3-pro-preview_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251129T125426901Z_gemini-3-pro-preview_seed124.jsonl", "pred": "B", "model_outputs": "Here is the step-by-step evaluation of the clinical scenario and options:\n\n1.  Diagnosis and Staging:\n    *   The patient has invasive squamous cell carcinoma with a depth of invasion of 2 mm and horizontal spread of 5 mm.\n    *   According to FIGO 2018 staging, a depth of invasion < 3 mm refers to Stage IA1.\n\n2.  Risk Factors:\n    *   The pathology report notes that Lymphovascular space invasion (LVSI) is extensively present.\n    *   While Stage IA1 without LVSI is considered very low risk, the presence of LVSI significantly increases the risk of lymph node metastasis and recurrence.\n\n3.  Guideline Analysis (NCCN):\n    *   Stage IA1 without LVSI: Cone biopsy with negative margins is generally considered sufficient treatment for fertility preservation (Option C would be correct if LVSI were absent).\n    *   Stage IA1 with LVSI: NCCN guidelines recommend valid fertility-sparing options that address the increased risk. These generally include:\n        *   Radical trachelectomy with pelvic lymph node dissection (Standard recommendation).\n        *   Cone biopsy *with pelvic lymph node dissection* (Category 2B recommendation).\n    *   Because of the LVSI, assessment of the pelvic lymph nodes is mandatory.\n\n4.  Evaluating the Options:\n    *   A. Simple trachelectomy: This procedure removes the cervix but not the parametrium. While the field is moving toward less radical surgery (e.g., the SHAPE trial), NCCN guidelines for LVSI-positive disease still emphasize lymph node assessment. This option does not explicitly mention lymph node assessment, and standard guidelines typically list radical trachelectomy or cone + lymph node dissection for this scenario.\n    *   B. Radical trachelectomy with pelvic lymph node assessment: This option aligns with NCCN guidelines for Stage IA1 with LVSI. It addresses the local disease (via trachelectomy, often removing parametria to ensure clear margins given the risk factors) and, crucially, assesses the lymph nodes.\n    *   C. Conization with negative margins is sufficient: This is incorrect because \"sufficient\" implies no further treatment is needed. Due to the presence of LVSI, observation alone is unsafe; lymph node assessment is required.\n    *   D. Simple hysterectomy: This is not a fertility-sparing option.\n    *   E. Pelvic radiation therapy: This would destroy ovarian function and the uterus, making it inappropriate for a patient desiring fertility who has surgically treatable early-stage disease.\n\n5.  Conclusion:\n    The presence of LVSI mandates lymph node evaluation. Among the options provided, Option B is the specific fertility-sparing treatment recommended by NCCN guidelines that adequately addresses the risk associated with LVSI.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_gemini-3-pro-preview_p04", "question_id": "ABMS20260101_gemini-3-pro-preview_p04-005", "question": "A patient with a known diagnosis of Erythropoietic Protoporphyria (EPP) is undergoing a prolonged laparotomy. Which of the following intraoperative interventions is most critical to prevent cutaneous injury in this specific patient?", "options": ["Avoidance of nitrous oxide", "Placement of yellow filters over the operating lights", "Strict avoidance of volatile anesthetics", "Administration of high-dose corticosteroids", "Maintenance of normothermia to prevent precipitation"], "answer": "B", "answer_index": 1, "explanation": "Patients with EPP accumulate protoporphyrin IX, which is phototoxic upon exposure to light in the violet/blue spectrum (Soret band, ~400-410 nm). Standard operating lights emit significant energy in this range, causing severe phototoxic skin burns and potential intestinal injury during laparotomy. Yellow filters block this specific wavelength.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "abms_specialty": "Anesthesiology", "abms_source": "target_topic", "source_label_raw": "Anesthesiology", "source_quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "source_question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-004", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gemini-3-pro-preview/20251223T232137723Z_gemini-3-pro-preview_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251223T232137723Z_gemini-3-pro-preview_seed128.jsonl", "pred": "B", "model_outputs": "Here is the step-by-step reasoning for the correct answer:\n\n1.  Understand the Pathology: Erythropoietic Protoporphyria (EPP) is a cutaneous porphyria caused by a deficiency in the enzyme ferrochelatase. This leads to the accumulation of protoporphyrin IX in red blood cells, plasma, and skin.\n2.  Identify the Specific Risk: Protoporphyrin IX is a photosensitizer. When exposed to light—particularly in the Soret band (approximately 400–410 nm, blue-violet light)—it absorbs energy and generates reactive oxygen species, leading to cellular damage. Patients present with painful accumulation of fluid and burns upon light exposure.\n3.  Surgical Implications: Operating room lights are extremely bright and emit a broad spectrum of light, including the wavelengths that trigger reactions in EPP. Prolonged exposure during surgery (like a laparotomy) puts the patient at high risk for drastic cutaneous burns and potential damage to internal tissues exposed to the light.\n4.  Evaluate the Options:\n    *   A: Nitrous oxide is generally considered safe for use in patients with porphyria.\n    *   B: Placing yellow filters over operating lights blocks the transmission of blue-violet light (the wavelengths most responsible for exciting protoporphyrins). This is the standard of care to prevent phototoxic injury in EPP patients during surgery.\n    *   C: Volatile anesthetics are generally considered safe in EPP. Unlike the acute hepatic porphyrias (e.g., Acute Intermittent Porphyria), EPP is not typically associated with drug-induced neurovisceral crises. Therefore, strict avoidance is not the primary concern.\n    *   D: Corticosteroids are not the primary prophylaxis for preventing phototoxicity in EPP.\n    *   E: Normothermia is standard care but is not the specific intervention to prevent the biochemical injury associated with EPP.\n\nConclusion: The most critical intervention to prevent cutaneous injury is minimizing exposure to the specific wavelengths of light that activate the accumulated protoporphyrins.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_gemini-3-pro-preview_p04", "question_id": "ABMS20260101_gemini-3-pro-preview_p04-006", "question": "A 22-year-old male presents with hypersomnia, hyperphagia, and hypersexuality occurring in distinct episodes lasting two weeks, separated by months of normal behavior. During episodes, he exhibits derealization. Which of the following pharmacologic agents has the strongest evidence for preventing future episodes of this syndrome?", "options": ["Modafinil", "Lithium", "Methylphenidate", "Fluoxetine", "Lorazepam"], "answer": "B", "answer_index": 1, "explanation": "The clinical presentation is classic for Kleine-Levin Syndrome (KLS). While symptomatic treatment involves stimulants, Lithium is the mood stabilizer with the most reported efficacy in reducing the frequency and intensity of the cycling episodes, although evidence is limited to case series and small studies.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "abms_specialty": "Psychiatry", "abms_source": "target_topic", "source_label_raw": "Psychiatry", "source_quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "source_question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-007", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gemini-3-pro-preview/20251223T232137723Z_gemini-3-pro-preview_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251223T232137723Z_gemini-3-pro-preview_seed128.jsonl", "pred": "B", "model_outputs": "Based on the clinical presentation, the patient is suffering from Kleine-Levin Syndrome (KLS). This is a rare disorder that predominantly affects adolescent males and is characterized by recurrent episodes of severe hypersomnia (sleeping up to 20 hours a day) accompanied by cognitive and behavioral disturbances. Common symptoms include hyperphagia (compulsive eating), hypersexuality, irritability, and derealization. Importantly, patients return to their baseline level of functioning between episodes.\n\nRegarding the management of KLS:\n*   Symptomatic treatment: Stimulants like Modafinil (Option A) or Methylphenidate (Option C) are sometimes used to combat sleepiness during an active episode, but they do not prevent future episodes and may exacerbate irritability.\n*   Prophylactic treatment: The goal is to prevent the recurrence of episodes. Mood stabilizers represent the primary class of medications used for this purpose. Lithium (Option B) has the strongest evidence in the literature for reducing the frequency and severity of episodes or preventing them in patients with Kleine-Levin Syndrome. Other mood stabilizers like carbamazepine or valproate are sometimes used but are generally considered second-line to Lithium in reported efficacy.\n*   Fluoxetine (Option D) and other antidepressants have generally not been found effective for prevention.\n*   Lorazepam (Option E) is not indicated for the prevention of KLS episodes.\n\nTherefore, Lithium is the most appropriate choice for preventing future episodes.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_gemini-3-pro-preview_p04", "question_id": "ABMS20260101_gemini-3-pro-preview_p04-007", "question": "A 40-year-old female presents with a 3 cm mass in the tail of the pancreas. CT imaging shows a well-circumscribed lesion with peripheral calcification. EUS-FNA is non-diagnostic but shows glycogen-rich cuboidal cells. What is the most likely diagnosis?", "options": ["Serous cystadenoma", "Mucinous cystic neoplasm", "Solid pseudopapillary neoplasm", "Pancreatic neuroendocrine tumor", "Acinar cell carcinoma"], "answer": "A", "answer_index": 0, "explanation": "Serous cystadenomas are benign lesions often found in the pancreatic tail. The classic description includes a 'honeycomb' appearance and a central scar with calcification (though peripheral calcification can occur). The key histologic feature is glycogen-rich cuboidal cells (clear cells) that stain positive for PAS. They have virtually no malignant potential.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "abms_specialty": "General Surgery", "abms_source": "target_topic", "source_label_raw": "General Surgery", "source_quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "source_question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-018", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gemini-3-pro-preview/20251223T232137723Z_gemini-3-pro-preview_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251223T232137723Z_gemini-3-pro-preview_seed128.jsonl", "pred": "A", "model_outputs": "The patient's presentation features a pancreatic mass with specific characteristics. Let's break down the findings to differentiate between the options:\n\n1.  Demographics and Location: A 40-year-old female with a mass in the tail of the pancreas.\n    *   Serous Cystadenoma (A): Can occur in any part of the pancreas; more common in females; median age is often older (60s) but can occur at 40.\n    *   Mucinous Cystic Neoplasm (B): Occurs almost exclusively in females (99%), typically middle-aged (mean 40-50), and predominantly in the body/tail (>95%).\n    *   Solid Pseudopapillary Neoplasm (C): Typically young females (mean age ~28), often in the tail.\n    *   Both B and C fit the demographic/location profile very well, often better than A.\n\n2.  Imaging (CT):\n    *   Peripheral calcification: This is classically referred to as \"egg-shell\" calcification and is a buzzword strongly associated with Mucinous Cystic Neoplasms (B) (specifically suggesting premalignant/malignant potential).\n    *   Serous Cystadenoma (A): Classically presents with a central \"sunburst\" calcification within a central scar. However, calcifications can vary.\n\n3.  Cytology (EUS-FNA):\n    *   \"Glycogen-rich cuboidal cells\": This is the definitive histologic description of the cells lining a Serous Cystadenoma. The cytoplasm of these cells is clear due to high glycogen content (Periodic acid-Schiff (PAS) positive, diastase sensitive).\n    *   Mucinous Cystic Neoplasm (B): Lined by tall, columnar, mucin-producing epithelium (PAS positive, diastase resistant) supported by ovarian-type stroma.\n    *   Solid Pseudopapillary Neoplasm (C): Shows branching papillae with myxoid stroma and uniform cells with nuclear grooves.\n    *   Neuroendocrine Tumor (D): Shows cells with \"salt-and-pepper\" chromatin.\n\nConclusion:\nWhile the imaging finding of \"peripheral calcification\" and the demographics might initially suggest a Mucinous Cystic Neoplasm, clinical vignettes in pathology/medical exams prioritize the cytological/histological findings as the \"gold standard\" for diagnosis. The finding of \"glycogen-rich cuboidal cells\" is specific to Serous Cystadenoma and excludes the other mucin-producing or neuroendocrine tumors. This represents a case where the biopsy provides the definitive diagnosis over the radiographic appearance.\n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_gemini-3-pro-preview_p04", "question_id": "ABMS20260101_gemini-3-pro-preview_p04-008", "question": "A 26-year-old female with a history of sensorineural hearing loss and short stature presents with acute onset aphasia and right-sided hemiparesis. MRI shows a T2-hyperintense lesion in the left temporal lobe that does not conform to a vascular territory. Serum lactate is elevated. Which of the following agents is indicated for the acute management of this condition?", "options": ["Intravenous Tissue Plasminogen Activator (tPA)", "Intravenous Arginine", "Intravenous Heparin", "High-dose Aspirin", "Plasma Exchange"], "answer": "B", "answer_index": 1, "explanation": "The clinical picture (stroke-like episode not respecting vascular territories, hearing loss, elevated lactate) is classic for MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes). The stroke-like episodes are due to metabolic failure and microvascular angiopathy (nitric oxide deficiency), not thrombotic occlusion. Intravenous Arginine is the recommended acute treatment to improve nitric oxide availability and cerebral blood flow. tPA is not indicated and could be harmful.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "abms_specialty": "Neurology", "abms_source": "topics_mapped", "source_label_raw": "Neurology", "source_quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "source_question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-007", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gemini-3-pro-preview/20251129T125426901Z_gemini-3-pro-preview_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251129T125426901Z_gemini-3-pro-preview_seed123.jsonl", "pred": "B", "model_outputs": "This patient presents with a clinical syndrome characteristic of MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes). The key features supporting this diagnosis include:\n1.  Patient Demographics and History: Young age, short stature, and sensorineural hearing loss are classic signs of mitochondrial disorders.\n2.  Acute Presentation: Stroke-like episodes (aphasia, hemiparesis) in a young patient.\n3.  Radiology: The MRI finding of a lesion that does not conform to a vascular territory is a hallmark of metabolic strokes in MELAS (often affecting the temporal or occipital lobes).\n4.  Labs: Elevated serum lactate is a sensitive marker for mitochondrial dysfunction.\n\nManagement Analysis:\n*   Intravenous Arginine (Option B): The pathophysiology of stroke-like episodes in MELAS is thought to involve mitochondrial angiopathy and a deficiency of nitric oxide, leading to impaired vasodilation in the microvasculature. L-arginine is a nitric oxide precursor. Clinical studies and guidelines recommend the use of intravenous L-arginine during the acute phase of a stroke-like episode to improve perfusion and reduce neuronal damage.\n*   Intravenous tPA (Option A): These episodes are not caused by thrombotic occlusion of large arteries. tPA is not indicated and carries hemorrhagic risks without addressing the underlying metabolic/microvascular pathology.\n*   Intravenous Heparin (C) and High-dose Aspirin (D): Anticoagulation and antiplatelet therapy treat thromboembolic strokes, not metabolic strokes. Furthermore, salicylates should be used with caution in mitochondrial disease due to potential mitochondrial toxicity, although low doses are sometimes used.\n*   Plasma Exchange (E): This is indicated for autoimmune or antibody-mediated neurological conditions, not genetic metabolic disorders like MELAS.\n\nTherefore, intravenous arginine is the indicated agent for the acute management of stroke-like episodes in MELAS.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_gemini-3-pro-preview_p04", "question_id": "ABMS20260101_gemini-3-pro-preview_p04-009", "question": "A 14-year-old boy with a history of exercise-induced syncope is diagnosed with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) confirmed by an RyR2 mutation. He is compliant with high-dose Nadolol. A repeat exercise stress test shows a reduction in arrhythmia burden, but he still develops runs of bidirectional ventricular tachycardia at peak exertion. Which of the following is the best next step in management?", "options": ["Switch Nadolol to Metoprolol Succinate", "Add Flecainide", "Perform Radiofrequency Ablation of the ventricular focus", "Implant a dual-chamber pacemaker", "Add Verapamil"], "answer": "B", "answer_index": 1, "explanation": "In patients with CPVT who have breakthrough arrhythmias despite optimal beta-blocker therapy (preferably Nadolol or Propranolol), the addition of Flecainide is the guideline-recommended next step. Flecainide has a direct blocking effect on the cardiac ryanodine receptor (RyR2), addressing the underlying mechanism. Radiofrequency ablation is generally ineffective due to the polymorphic/multifocal nature of the arrhythmia.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Cardiovascular", "abms_specialty": "Cardiovascular", "abms_source": "topics_mapped", "source_label_raw": "cardiology", "source_quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "source_question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-006", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gemini-3-pro-preview/20251129T125426901Z_gemini-3-pro-preview_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251129T125426901Z_gemini-3-pro-preview_seed123.jsonl", "pred": "B", "model_outputs": "Explanations and Reasoning:\n\n1.  Diagnosis and Pathophysiology: The patient has Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), confirmed by an RyR2 mutation. This condition is characterized by adrenergic-induced intracellular calcium overload leading to delayed afterdepolarizations and ventricular arrhythmias, typically bidirectional or polymorphic VT.\n\n2.  First-Line Therapy: The standard first-line treatment for CPVT is the use of non-selective beta-blockers, such as Nadolol or Propranolol. This patient is already on high-dose Nadolol and is compliant.\n\n3.  Refractory Disease: Despite optimal beta-blocker therapy, the patient demonstrates breakthrough arrhythmias (runs of bidirectional VT) during an exercise stress test. This indicates incomplete control and a continued risk of syncope or sudden cardiac death.\n\n4.  Second-Line Therapy: Current guidelines (such as those from the AHA/ACC/HRS and ESC) recommend the addition of Flecainide for patients with CPVT who have recurrent syncope or persistent ventricular arrhythmias despite therapeutic beta-blocker use. Flecainide is a Class Ic antiarrhythmic that blocks sodium channels but also has a specific action in CPVT by inhibiting the Ryanodine receptor (RyR2) opening, thereby directly countering the mechanism of calcium release.\n\n5.  Evaluation of Incorrect Options:\n    *   A. Switch Nadolol to Metoprolol Succinate: Nadolol (non-selective) is preferred over Metoprolol (beta-1 selective) for CPVT. Switching to Metoprolol is associated with a higher rate of treatment failure.\n    *   C. Perform Radiofrequency Ablation: CPVT is a global myocardial channelopathy, making focal ablation generally ineffective and not a standard second-line approach. Left Cardiac Sympathetic Denervation (LCSD) is the preferred surgical intervention if medications fail.\n    *   D. Implant a dual-chamber pacemaker: While an Implantable Cardioverter Defibrillator (ICD) might be considered for cardiac arrest survivors or medication-refractory cases, a standard pacemaker does not treat the tachycardia. Furthermore, optimizing medical therapy to suppress the arrhythmia is prioritized to avoid ICD shocks (which can be pro-arrhythmic in CPVT due to pain/anxiety increasing adrenergic surge).\n    *   E. Add Verapamil: Calcium channel blockers like Verapamil have shown limited efficacy in CPVT compared to Flecainide and are not the preferred add-on agent.\n\n6.  Conclusion: The best next step to suppress the exercise-induced arrhythmias in a patient already on optimal beta-blocker therapy is to add Flecainide.\n\nThe answer is (B)"}, {"quiz_id": "ABMS20260101_gemini-3-pro-preview_p04", "question_id": "ABMS20260101_gemini-3-pro-preview_p04-010", "question": "A 32-year-old female presents with amenorrhea and galactorrhea. MRI reveals a 4.5 cm pituitary macroadenoma with invasion into the cavernous sinus. Visual fields are intact. Serum prolactin is reported as 145 ng/mL (Reference: <25 ng/mL). Which of the following is the most appropriate next step in management?", "options": ["Option A: Referral for transsphenoidal resection", "Option B: Stereotactic radiosurgery", "Option C: Measurement of prolactin in diluted serum", "Option D: Octreotide scintigraphy", "Option E: Bilateral inferior petrosal sinus sampling"], "answer": "C", "answer_index": 2, "explanation": "A 4.5 cm prolactinoma should typically produce prolactin levels >1,000-10,000 ng/mL. A mildly elevated level in the setting of a giant adenoma suggests the 'Hook Effect,' where excessive antigen saturates the assay antibodies, preventing sandwich formation and leading to a falsely low result. Diluting the sample (1:100) reveals the true elevated value. Confirming a prolactinoma is crucial because dopamine agonists (cabergoline) are the first-line treatment, not surgery.", "generator_model": "gemini-3-pro-preview", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Endocrine", "abms_specialty": "Endocrine", "abms_source": "topics_mapped", "source_label_raw": "endocrinology", "source_quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed127", "source_question_id": "20251129T125426901Z_gemini-3-pro-preview_seed127-005", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/gemini-3-pro-preview/20251129T125426901Z_gemini-3-pro-preview_seed127", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251129T125426901Z_gemini-3-pro-preview_seed127.jsonl", "pred": "C", "model_outputs": "This patient has a very large pituitary tumor (4.5 cm macroadenoma) but a serum prolactin level that is only moderately elevated (145 ng/mL). There is a significant discrepancy between the tumor size and the prolactin level.\n\nTypically, prolactinomas secrete prolactin in proportion to their size. A rough rule of thumb is that prolactin levels generally exceed 200 ng/mL in macroadenomas (>1 cm) and are often >1,000 ng/mL or significantly higher in invasive giant adenomas (>4 cm) like this one.\n\nA prolactin level of 145 ng/mL in the setting of a 4.5 cm mass suggests two main possibilities:\n1.  \"Stalk Effect\": The tumor is a non-functioning adenoma (not secreting prolactin) or another non-prolactinoma mass compressing the pituitary stalk, thereby preventing dopamine (which inhibits prolactin) from reaching the normal pituitary tissue. This usually results in prolactin levels <150–200 ng/mL.\n2.  \"Hook Effect\": The tumor is actually a giant prolactinoma secreting massive amounts of prolactin (e.g., >5,000–10,000 ng/mL), but the assay is saturated. In immunoradiometric assays, an overwhelming amount of antigen (prolactin) prevents the formation of the \"sandwich\" required for signal detection, resulting in a falsely low reported value.\n\nDistinguishing between these two is critical for management. If it is a prolactinoma (Hook Effect), the first-line treatment is medical therapy with dopamine agonists (e.g., cabergoline), which causes dramatic tumor shrinkage and lowers prolactin levels. If it is a non-functioning adenoma (Stalk Effect), medical therapy will not shrink the tumor, and surgical intervention (transsphenoidal resection) is likely necessary given the size and invasion.\n\nTo rule out the Hook Effect, the laboratory must dilute the serum sample (1:100) and re-measure the prolactin. If the level increases significantly after dilution, the diagnosis is a giant prolactinoma. If the level remains low, it confirms a non-functioning adenoma with the stalk effect.\n\nA. Surgery is not the next step because if this is a prolactinoma, it should be treated medically.\nB. Radiosurgery is a second- or third-line treatment.\nD. Octreotide scintigraphy is not indicated for workup of prolactinoma vs. non-functioning adenoma.\nE. IPSS is used for the workup of Cushing syndrome.\n\nThe answer is (C)"}]